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PURPOSE. Deficiencies in enzymes involved in proteoglycan
(PG) turnover underlie a number of rare mucopolysacchari-
doses (MPS), investigations of which can considerably aid un-
derstanding of the roles of PGs in corneal matrix biology. Here,
the authors analyze novel pathologic changes in MPS VII (Sly
syndrome) to determine the nature of PG-collagen associations
in stromal ultrastructure.
METHODS. Transmission electron microscopy and electron to-
mography were used to investigate PG-collagen architectures
and interactions in a cornea obtained at keratoplasty from a
22-year-old man with MPS VII, which was caused by a com-
pound heterozygous mutation in the GUSB gene.
RESULTS. Transmission electron microscopy showed atypical
morphology of the epithelial basement membrane and Bow-
man’s layer in MPS VII. Keratocytes were packed with cyto-
plasmic vacuoles containing abnormal glycosaminoglycan
(GAG) material, and collagen fibrils were thinner than in nor-
mal cornea and varied considerably throughout anterior
(14–32 nm), mid (13–42 nm), and posterior (17–39 nm) re-
gions of the MPS VII stroma. PGs viewed in three dimensions
were striking in appearance in that they were significantly
larger than PGs in normal cornea and formed highly extended
linkages with multiple collagen fibrils.
CONCLUSIONS. Cellular changes in the MPS VII cornea resemble
those in other MPS. However, the wide range of collagen fibril
diameters throughout the stroma and the extensive matrix
presence of supranormal-sized PG structures appear to be
unique features of this disorder. The findings suggest that the
accumulation of stromal chondroitin-, dermatan-, and heparan-
sulfate glycosaminoglycans in the absence of -glucuronidase-
mediated degradation can modulate collagen fibrillogenesis. (In-
vest Ophthalmol Vis Sci. 2011;52:6720–6728) DOI:10.1167/
iovs.11-7377
The mucopolysaccharidoses (MPS) are a group of lysosomalstorage diseases caused by inherited defects in specific
enzymes involved in the degradation of glycosaminoglycans
(GAGs).1–3 The result is a widespread accumulation of derma-
tan sulfate (DS), chondroitin sulfate (CS), heparan sulfate (HS),
or keratan sulfate (KS) in the majority of organs and tissues and
a wide range of clinical manifestations. Ocular involvement
attributed to GAG deposition in MPS includes progressive cor-
neal clouding, glaucoma, retinal degeneration, and optic disc
swelling followed by its atrophy.4 In a mouse model of MPS
VII, progressive photoreceptor death has also been observed.5
The cornea is affected in all the MPS subtypes classified to date,
with a significant overlap of corneal phenotype between, and
also within, the MPS types and a variety of treatment op-
tions.6,7
MPS VII (Sly syndrome; Mendelian Inheritance in Man
(MIM) #253220) is a rare, autosomal recessive, inherited con-
dition with an estimated incidence of 1 in 250,000 births,
which is one of the lowest of all MPS. Accumulation of unde-
graded GAGs typically leads to short stature, bone dysplasia,
hepatosplenomegaly, hydrops fetalis, and mental retarda-
tion.8,9 The course of the disease is considered clinically atten-
uated if there is no hydrops fetalis or severe mental retardation
and if the condition does not lead to death within a year.8 Most
children with MPS VII live into teenage or young adult years.
Various approaches toward therapy have been investigated
in mutant MPS VII mice, including bone marrow transplanta-
tion,10 enzyme replacement therapy,11 transplacental delivery
of the deficient enzyme tagged to Fc into the fetal circulation,12
gene therapy,13,14 encapsulation,15 and stem cell therapy.16
However, no effective treatment is yet available for affected
human patients. MPS VII is caused by deficiencies of -glucu-
ronidase enzyme (GUSB), leading to an accumulation of DS,
HS, and CS GAGs in the cells and tissues.17 Forty-nine unique
disease-causing mutations in the -glucuronidase gene (GUSB
MIM #611499) have been identified in persons with MPS VII
from various populations. Heterogeneity of pathogenic
changes, with different effects on the function of the mutant
proteins, manifests as extensive clinical variability among pa-
tients with MPS VII.18
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Proteoglycans (PGs) with their GAG side chains, in partic-
ular those of the small leucine-rich PG family of molecules, are
implicated in the regulation of fibrillar order in cornea. Recent
studies on corneal three-dimensional structure using electron
tomography have provided new insights into how PGs may
help to maintain the ordered architecture of the stroma essen-
tial for tissue transparency.19–21 Here, we describe a case of
MPS VII in which grafting was carried out to treat a reduction
of corneal transparency. Clinical, biochemical, molecular ge-
netic, histologic, and ultrastructural examinations of explanted
MPS VII corneal tissue were performed, with comparisons with
data obtained from a healthy human donor cornea acquired
from an eye bank. Data indicate that disturbance in PG turn-
over resulting from a GUSB deficiency leads to alterations in
both fibrillar and interfibrillar components of the corneal
stroma.
MATERIALS AND METHODS
The study conformed to the tenets of the Helsinki Declaration and local
ethics codes.
Medical and Ocular History
The patient reported here was a male, an only child, born to healthy,
unrelated parents after an unremarkable pregnancy. Clinical features
suggesting MPS diagnosis were present at birth. The -glucuronidase
activity in isolated leukocytes was 2% of controls. Molecular genetic
analysis of the GUSB gene revealed compound heterozygosity for two
missense mutations, c.[155CT]  [1120CT], leading to amino acid
changes p.Ser52Phe and p.Arg374Cys.22 Medical examination at the
age of 24 years revealed short stature (155 cm), a body weight of 65 kg,
and head circumference 61 cm, plus retroflexion of the head with a
short neck, sternal prominence, lumbar hyperlordosis, and hepato-
splenomegaly. An x-ray survey showed typical signs of dysostosis
multiplex. There were thickened aortic and mitral valves on echocar-
diography and an obstructive type of ventilation with a forced vital
capacity of 74%. The urinary GAG excretion, measured on several
occasions, was increased between 8 and 25 g/mol creatinine compared
with a normal value in adults of 1.8  0.6 g/mol,23 with higher
fractions of CS and DS. The patient was not mentally retarded and was
able to read, and several IQ tests performed since childhood revealed
scores of 81 to 85.
At 5 years of age, the patient’s best-corrected visual acuity (BCVA)
was 0.4 in both eyes and mild corneal clouding was noticed. Refraction
was4.0/5.0 D 7° in the right eye and3.0/4.5 D 174° in the
left. At 14 years of age, the patient was referred to the Department of
Ophthalmology in Prague with BCVAs of 0.33 (right eye) and 0.4 (left
eye). Because of progressive corneal clouding, a penetrating kerato-
plasty (8-mm diameter button) was performed in the right eye at the
age of 20 years and in the left eye at the age of 22 years. Before surgery,
FIGURE 1. Ocular findings in a pa-
tient with mucopolysaccharidosis
VII. (A, B) Diffuse fine cloudiness in
corneal stroma of the right eye be-
fore surgery. (C) Videotopography
reveals regular astigmatism in the left
eye before grafting. (D) Six months
after keratoplasty in the right eye. (E)
Normal postoperative appearance of
fundus in the right eye. (F) Normal
appearance of the macular region on
OCT in the right eye.
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diffuse opacification involving all corneal layers was observed bilater-
ally (Fig. 1), with a BCVA of 0.33 in the right eye and 0.11 in the left.
In both eyes the anterior segment was normal, as were intraocular
pressure (IOP) measurements, and strabismus was not detected. Reg-
ular astigmatism was documented in the left eye (examination not
performed in the right eye; Fig. 1). No complications were encoun-
tered during or after surgery, and at the last evaluations, 2.5 years and
6 months after right and left keratoplasty, respectively, both corneas
remained clear (Fig. 1), with normal IOP and uncorrected visual acu-
ities of 0.25 in the right eye and 0.4 in the left. To the best of our
knowledge, there has been only one previous report on corneal trans-
plantation in MPS VII, performed on a 15-year-old patient with mental
retardation, which prevented detailed measurement of the visual acu-
ity.24 In our patient’s right eye, postoperative fundus photography and
optical coherence tomography documented, for the first time in an
MPS, no abnormalities of the macula area (Fig. 1).
Transmission Electron Microscopy and
Electron Tomography
Immediately after surgery, small (approximately 1 mm  5 mm),
full-thickness biopsy samples taken from the center of the left cornea
were fixed for 20 hours at room temperature with 2.5% glutaraldehyde
in 25 mM sodium acetate buffer and 0.1 M magnesium chloride, pH
5.7, which included 0.05% cuprolinic blue as a cationic stain for
sulfated PGs. Tissue was then contrast-enhanced using aqueous, then
50% ethanolic, 0.5% sodium tungstate, followed by dehydration in
ethanol. For collagen fibril diameter measurements, tissues were pre-
pared by fixation in 2.5% glutaraldehyde/2% paraformaldehyde in
0.1 M So¨rensen phosphate buffer, pH 7.4, for 3 hours, followed by
postfixation in 1% osmium tetroxide for 1 hour and en bloc contrast
in 0.5% aqueous uranyl acetate and subsequent dehydration. After
transfer through propylene oxide, tissue was infiltrated and embed-
ded in Araldite CY212 resin. For fibril diameter measurements,
ultrathin sections (90–100 nm thick, cut with a diamond knife)
were collected on uncoated G300 copper grids, and stained with
saturated aqueous uranyl acetate and lead citrate. For electron
tomography of PG ultrastructure, 120-nm-thick sections were col-
lected on G200 grids that were then stained with 1% aqueous
phosphotungstic acid and uranyl acetate. Sections were examined
in a transmission electron microscope (JEOL 1010; JEOL, Tokyo,
Japan) equipped with a charge-coupled device camera (Orius
SC1000; Gatan, Pleasanton, CA).
FIGURE 2. Electron micrographs of
epithelial basement membrane zone
in normal (A, C) and MPS VII cornea
(B, D) cornea. Bowman’s layer (Bl) is
distinctive in normal cornea (A, C)
but poorly defined, or absent, in MPS
VII (B, D). Anchoring fibrils (white
arrow) appear to insert directly into
superficial stroma (S) in MPS VII (D)
rather than into Bowman’s layer as in
normal cornea (C). Basal epithelial
cells (Ep) exhibit hemidesmosomes
(C, D; arrowheads). Basal lamina, dis-
tinctive in normal cornea (black ar-
rows), appears diffuse in MPS VII with
an underlying granular deposit (D).
Scale bars, 1m (A, B); 200 nm (C,D).
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For comparison with data obtained from the MPS VII cornea,
specimens of normal human cornea were also obtained and prepared
by the same methods of fixation. A left-right pair of human corneas,
unsuitable for use in transplantation, was acquired for research pur-
poses from the Northwest Lions Eye Bank (Seattle, WA) with full
informed consent and institutional approval. These tissues were the
subject of an earlier published study25 that details, in full, methods of
preparation before fixation.
Fibril diameter measurements were made on electron micrographs,
taken at 20,000 magnification, of the corneal tissue that had been
postfixed with osmium tetroxide. ImageJ software (developed by
Wayne Rasband, National Institutes of Health, Bethesda, MD; available
at http://rsb.info.nih.gov/ij/index.html) was used, with the measuring
tool calibrated against micrograph scale bars generated by imaging
software (Digital Micrograph; Gatan) and derived from images of a
2160 lines/mm diffraction grating acquired with the charge-coupled
device camera (Orius SC1000; Gatan). Areas were selected in which
fibrils appeared in sharply defined transverse sections. Straight-line
values were taken across the shortest diameter for each individual fibril
to minimize any error where the section plane might have deviated
from true transverse section and where irregular fibril profiles were
encountered. Histograms of fibril diameters were prepared using pre-
dictive analysis (SPSS 16; IBM, Armonk, NY).
For electron tomography, 10 nm colloidal gold particles were
added to both sides of the stained 120-nm–thick sections of cuprolinic
blue-contrasted tissue. The gold particles served as fiducial markers to
facilitate the alignment of a series of 60 images taken at 20,000
magnification and at 2° tilt increments from 60° to 60°. The image
sequence was processed through IMOD, ImageJ, and EM3D software
to generate a three-dimensional reconstruction of collagen-PG associ-
ations viewed in longitudinal section and was achieved according to
previously described techniques.19–21
RESULTS
The MPS VII cornea was surfaced by a normal, stratified epi-
thelium with hemidesmosomes visible on proximal mem-
branes of the basal cells (Fig. 2). However, the epithelial basal
lamina appeared diffuse compared with that in normal cornea
(Figs. 2C, 2D). An underlying granular deposit enveloped an-
choring fibrils that apparently inserted directly into superficial
stroma, as Bowman’s layer appeared undeveloped or absent
(Figs. 2B, 2D). Stromal keratocytes, typical of fibroblasts in
lysosomal storage disease, were mostly enlarged and charac-
terized by conspicuous distension of the lysosomal system by
whorl-like or granular contents of variable electron density
(Figs. 3A–D). All cells throughout the full thickness of the
corneal stroma appeared affected, though occasionally indi-
vidual cells were located with minimal, or preliminary, in-
dications of lysosomal accumulation (Fig. 3B). Keratocyte
cytoplasmic vacuole contents bound the cationic dye cupro-
linic blue, indicating intracellular sequestration of polyan-
ionic material presumed to be PGs (Fig. 3E). In some cells,
empty lucent vacuoles suggested extracellular release of
contents by degenerating keratocytes (Figs. 3A, 3D). Intras-
tromal vacuoles contained complexed dye (Fig. 3F), also
implying the release of compartmentalized PG or GAG cargo
from cells into the matrix, although whether these struc-
tures were membrane bound could not be conclusively
demonstrated. Descemet’s membrane and endothelial cells
exhibited no signs of lysosomal storage.
Stromal lamellae appeared compact in the MPS VII cornea,
but, unlike stromal lamellae in normal cornea (Figs. 4A, 4C,
4E), wide variations in collagen fibril diameter were evident
when viewed in transverse section and were readily located at
FIGURE 3. Keratocyte morphology
and granular accumulation in MPS
VII cornea. (A) Most keratocytes
throughout the corneal thickness, as
shown here in mid stroma, exhibit
evidence of lysosomal storage with
an accumulation of cytoplasmic vac-
uoles. Scale bar, 2.5 m. (B) Occa-
sional cells with minimal vacuole accu-
mulation are present. Scale bar, 1 m.
(C, D) Cytoplasmic vacuoles appear
with dense granular contents or empty
after extraction or release of contents.
Scale bar, 1 m. (E) Intracellular cu-
prolinic blue labeling (arrowheads) in-
dicates polyanionic material retained
within cellular vacuoles. Scale bar, 1
m. (F) Vacuoles and cuprolinic blue-
labeled contents may also be released
into the extracellular matrix. Scale bar,
250 nm.
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all depths throughout the stroma (Figs. 4B, 4D, 4F). In addition,
fibrils with irregular profiles were prevalent in the MPS VII
stroma (Fig. 4G). In contrast to normal cornea, accumulations
of long-spaced collagen appeared abundant in MPS VII.
Measurements of collagen fibrils in the control eye bank
cornea examined here showed a statistically normal distribu-
tion of fibril diameters throughout the stroma (Figs. 5A, 5C,
5E), with a trans-stromal mean of 23.53 nm compared with
published mean values of 26.0 nm.26 Fibril diameters ranged
from 14.6 to 29.0 nm (mean 23.0 nm, SD 2.1 nm; n 1278),
in the anterior stroma, to 15.8 to 31.0 nm (mean 23.9 nm, SD
2.0 nm; n  1268), in the mid stroma, and to 17.3 to 32.0 nm
(mean 23.8 nm, SD2.0 nm; n  1093) in the posterior
stroma. In the MPS VII cornea, collagen fibrils appeared regu-
larly packed, although fibrils were not of uniform diameter
(Figs. 4, 5). Small and large collagen fibrils were visible
throughout the stromal thickness, with abnormal diameters
especially prominent in the mid and posterior stroma (Fig. 5).
Measurements of fibril diameter at different depths in MPS VII
showed a broader range than was seen in normal cornea. Fibril
diameters ranged from 13.6 nm to 32.2 nm in the anterior
stroma (n 1104), from 12.7 nm to 41.6 nm in the mid stroma
(n  1026), and from 16.6 nm to 38.8 nm in the posterior
stroma (n  1136; Figs. 5B, 5D, 5F). A one-sample Kolmogo-
rov-Smirnov test showed that in the MPS VII cornea, none of
the fibril diameter distributions was normal at any of the
stromal depths examined (anterior, P 0.001; mid, P 0.000;
posterior, P  0.000). In the anterior stroma, the spectrum of
collagen fibril diameters was not as broad as in the mid and
posterior stroma but still differed significantly from the normal
cornea. Fibrils in the mid stroma showed indications of a
bimodal distribution of diameter measurements (Fig. 5D).
Proteoglycans visualized by cuprolinic blue staining in this
case of MPS VII appeared different from those in the normal
cornea (Fig. 6). In contrast to the fine filamentous or rounded
structures radiating from collagen fibrils in normal cornea
(Figs. 6A, 6B, 6E, 6F, 6I, 6J), they assumed a more elongated,
thicker, and more electron-dense appearance (Figs. 6C, 6D,
6G, 6H, 6K, 6L), apparently traversing several collagen fibrils
(Figs. 6G, 6K). These PG-dye complexes rarely exhibited reg-
ular D-periodic association with the fibrils or any interactions
with long-spacing collagen. Three-dimensional reconstruction
from electron tomography of collagen fibrils in longitudinal
section in MPS VII clearly showed that PGs traversed up to four
collagen fibrils and were also visible running axially along
FIGURE 4. Stromal ultrastructure. Col-
lagen fibrils in transverse section in nor-
mal (A, C, E) and MPS VII (B, D, F)
cornea at locations in anterior (A, B),
mid (C, D), and posterior (E, F)
stroma. Fibrils show wide variation in
diameter in MPS VII throughout the
stromal thickness, appearing generally
smaller overall than in normal tissue.
Scale bars, 100 nm. (G) In the MPS VII
cornea, deviation from the circular
profile of some fibrils in transverse sec-
tion suggests less regulated control of
fibril shape than in the normal cornea.
Scale bar, 25 nm.
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fibrils (Fig. 7 and Supplementary Movie S1, http://www.iovs.
org/lookup/suppl/doi:10.1167/iovs.11-7377/-/DCSupplemental).
DISCUSSION
Since its identification more than 30 years ago,27 the extreme
rarity of MPS VII has meant that investigations into its genetic
origins and phenotypic manifestations have been few. Varia-
tions in the severity of clinical symptoms between individual
cases in MPS VII, in contrast, have been well documented,3 and
in milder forms of the disease 10% of normal levels of -glucu-
ronidase has been demonstrated in cultured fibroblasts.28
Hence, some turnover, albeit reduced, of its substrates DS, CS,
and HS GAGs is still present. It should be emphasized, there-
fore, that the pathologic features we describe in this single case
of MPS VII cornea may not necessarily be representative of all
disease variants, though comparisons with normal cornea illus-
trate significant differences in matrix ultrastructure. The patho-
genic variants in our case are a very rare cause of MPS VII. The
c.155CT change located in exon 1 has been found only in our
patient, whereas c.1120CT has been further detected in one
allele of a German proband.8 It is predicted that the pheno-
typic severity in our patient is predominantly influenced by the
c.155CT mutation, which causes total destruction of -glu-
curonidase enzyme activity in transfected cells. The
c.1120CT mutation leads to a residual activity of 5.5% com-
pared with the wild type,28 which, in this patient, might have
led to an absence of the mental retardation usually observed in
patients with MPS VII.
Recently, our understanding of -glucuronidase deficiency
in MPS VII has been advanced by studies of model systems in
animals.29 However, tissue studies of ocular manifestations of
the clinical disease in humans, particularly in the cornea, have
been limited by the infrequent availability of surgical speci-
mens from keratoplasty.24 Consequently, to our knowledge,
there have been no previous reports of corneal matrix changes
at the fibrillar level arising from -glucuronidase–deficient
GAG turnover in MPS VII. Bergwerk et al.24 showed vacuoles
and inclusions in keratocytes by electron microscopy in MPS
VII but made no mention of alterations in collagen and PG
organization of the extracellular matrix such as those we de-
scribe, and that, along with the presence of abnormal cells in
the stroma, were likely related to the loss of transparency.
Progressive corneal opacification affects all forms of MPS,6,7
and although the severity of the opacification differs across
these conditions, there is a common appearance of corneal
keratocytes, as we describe here in MPS VII, with a massed
accumulation of GAGs in the endosomal-lysosomal compart-
FIGURE 5. Histograms showing mea-
surements of collagen fibril diameters
in normal (A, C, E) and MPS VII (B, D,
F) cornea. Anterior stromal collagen
fibril diameters are given here. (A)
Normal cornea: fibril diameter range,
14.6 to 29.0 nm; mean, 23.0 nm, SD
2.1 nm (n  1278). (B) MPS VII cor-
nea: fibril diameter range, 13.6 to 32.2
nm (n  1104). Mid stromal collagen
fibril diameters are given here. (C).
Normal cornea: fibril diameter range,
15.8 to 31.0 nm; mean, 23.9 nm, SD
2.0 nm (n  1268). (D) MPS VII cor-
nea: fibril diameter range, 12.7 to 41.6
nm (n  1026). Posterior stromal col-
lagen fibril diameters are given here.
(E) Normal cornea: fibril diameter
range, 17.3 to 31.9 nm; mean, 23.8
nm, SD  2.04 nm (n  1093). (F)
MPS VII cornea: fibril diameter range,
16.6 to 38.8 nm (n  1136).
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ment of the cells. Similar cellular pathology occurs, for exam-
ple, in Morquio syndrome (MPS IV), in which the degradation
of KS GAG is impaired and in which, as documented here in
MPS VII, alterations in epithelial basement membrane and
aberrant Bowman’s layer are also present.30,31 Cuprolinic blue-
stained deposits have also been reported inside keratocytes in
MPS I-H (Hurler syndrome),32 in which -L-iduronidase defi-
ciency leads to an accumulation of HS and DS, and in MPS VI
(Maroteaux-Lamy syndrome),33 in which DS accumulates as a
result of N-acetylgalactosamine 4-sulfatase deficiency.
In addition to the changes in keratocyte morphology indic-
ative of overload on the lysosomal degradation pathways for
GAGs, the corneal stroma in MPS contains supranormal levels
of the partially degraded molecules, variously described as
granular or membranous material.24,30,31 It is likely that excess
extracellular GAG may arise both from newly secreted material
FIGURE 6. Proteoglycans visualized
by cuprolinic blue in normal cornea
(two left-hand columns) and MPS VII
cornea (two right-hand columns) in
anterior (top row), mid (central row),
and posterior (bottom row) stroma. In
normal cornea, proteoglycans appear
as fine filaments radiating from colla-
gen fibrils in transverse (A, E, I) and
longitudinal (B, F, J) section. In MPS
cornea, filaments appear larger in
transverse (C, G, K) and longitudinal
(D, H, L) section. Filaments traverse
several collagen fibrils (G, K; arrow-
heads) and sometimes run axially over
several D-periods (L; arrow). Scale bar,
150 nm.
FIGURE 7. 3D reconstruction of colla-
gen fibrils, shown here in longitudinal
section, and associated proteoglycans
in posterior stroma of MPS VII cornea.
Collagen, false-colored blue, pro-
teoglycans, yellow. Proteoglycans both
traverse and run axially with respect to
fibril orientation and link up to four
collagen fibrils. Scale bar, 100 nm. To
obtain a 3D impression from the stereo
paired images, display images approx-
imately 6 to 7 cm apart and apply your
nose onto the page/screen between
the two images. Keeping both eyes
open, view the two out-of-focus im-
ages superimposed; slowly move to 30
to 40 cm from eye to the page/screen;
when you can focus, you should see
three images. The middle one should
have appreciable depth; ignore the flat
images on either side.
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and from incomplete degradation products of the extracellular
matrix. Although more than 50% of newly synthesized PGs are
thought to be degraded through the lysosomal system in nor-
mal tissues, without extracellular secretion, in MPS, partially
degraded intracellular GAG breakdown fragments could poten-
tially be trafficked into the extracellular space. One clear route
for this appears to be through the degeneration of keratocytes
and the release of storage vacuoles pericellularly, after disrup-
tion of the plasma membrane. Alternatively, increased intracel-
lular calcium associated with membrane damage has been
shown to lead to lysosomal exocytosis, with up to 24% involve-
ment of peripheral lysosomes in primary fibroblasts in vitro.34
Degradation pathways of PGs in the matrix outside the cell are
also incompletely understood. Small PGs are probably released
from their collagen associations by the activity of extracellular
metalloproteases on their protein cores,35 after which they are
taken into the cells by endocytosis for sequential breakdown in
the lysosomal system by endoglycosidases, exoglycosidases,
and sulfatases.36 The receptor-mediated process by which
small PGs, including decorin and lumican, either as whole PGs
or as partially digested fragments enter the cell may include
binding to Toll-like receptors now known to be present on
corneal cells37 and on phagocytes of the immune system. This
route is accepted as a potential conduit toward mediation of
inflammatory and immune responses in keratocytes,38 through
transformation to myofibroblasts, and by mononuclear cells.
The participation of -glucuronidase in GAG degradation
occurs at a relatively late stage in lysosomal degradation of
GAGs to produce small glycan fragments still carrying sulfate
groups. Accumulation of these, together with larger moieties
released from the matrix by proteolytic degradation, presum-
ably gives rise to a heterogeneous population of sulfated CS,
DS, and HS GAGs present as free matrix components in MPS
VII, which would be available for association by electrostatic
interaction with other structural components in the stroma.
We report here cuprolinic blue-complexed PG structures in
MPS VII cornea that greatly exceed in length those previously
reported in normal human corneas or indeed those in other
species. PGs in MPS VII often traversed multiple collagen
fibrils, sometimes up to four in number, and were either
orientated axially along fibrils or weaved through the extrafi-
brillar space laterally to the fibrils. Large cuprolinic blue–
positive structures have also been documented in the corneas
of Chst5 null mice, where they are branched, and are assumed
to be aggregated CS/DS proteoglycans.39,40 In a previous
study41 on Morquio syndrome in which turnover of KS GAG is
impaired, PG filaments visualized with cuprolinic blue also
appeared increased in length. Abnormally large cuprolinic
blue–positive structures were found as well in the stroma of
-L-iduronidase–deficient MPS I-H (Hurler syndrome)32 and
MPS I-S (Scheie syndrome) corneas.26 These observations sup-
port the concept that excessive free GAGs in the matrix have
the capacity to self-aggregate or to bind to existing matrix
constituents to generate supranormal-sized structures. Overall,
however, dye-complexed PGs in MPS VII, though larger, ap-
peared fewer in number than in normal cornea and without
abundant D-periodic collagen associations. Although evidence
is not available here, small leucine-rich proteoglycans may be
able to substitute functionally when the absence, or overpro-
duction, of one molecule might lead to an imbalance.42,43 Thus
compensatory downregulation of KS and KS-bearing core pro-
teins may occur in MPS VII, where matrix accumulation of CS
and DS leads to the formation instead of larger PG aggregates.
This may explain the apparent scarcity of small fibril–associ-
ated cuprolinic blue–stained filaments, which in the cornea are
presumed to be KS PGs in the MPS VII stroma.
The discovery of smaller than normal collagen fibril diame-
ters in MPS VII reported here is consistent with indications that
increased amounts of decorin result in smaller fibrils.44 How-
ever, though the enzyme defect in MPS VII would be expected
to cause an increase in DS as well as in CS and HS GAGs in the
matrix, whether core protein concentrations would also be
increased is unknown. Reduced fibril diameter was detected
throughout the stromal thickness, which is not surprising be-
cause decorin and DS/CS concentrations are not known to vary
with stromal depth. Alterations in collagen fibril morphology
have been reported previously in MPS I, IV, and VI, all of which
exhibited corneal opacities, but in all these the average fibril
diameter was increased.26,32,41,45 Bimodal distribution of fibril
diameter measurements, as detected in the mid stroma here,
was also previously reported in MPS IS (Scheie),26 MPS IV
(Morquio),41 and MPS IV (Hurler)32 and was interpreted as
fibril aggregation. The presence of irregular fibril profiles in the
MPS VII cornea suggests less regulated control of fibril shape
than in normal cornea. However, this is difficult to reconcile
with current evidence that indicates the deficiency of
decorin46,47 and of other small leucine-rich proteoglycans48
has been linked to aberrations in fibril form through uncon-
trolled lateral fibril growth in the absence of binding of these
molecules to the fibril surface. The mechanisms whereby ex-
cess matrix DS, CS, and HS GAGs in MPS VII might lead to
dysregulation of fibril shape are unknown.
MPS syndromes, including MPS VII, through deficiencies in
enzymes involved in GAG turnover, lead to a range of altera-
tions in both interfibrillar and fibrillar extracellular matrix com-
ponents of the cornea and yet have a common outcome in loss
of corneal function through stromal opacity. They emphasize
the complexities of interactions between matrix components
and the deficiencies in our knowledge of their functions and
pathways of remodeling. Further studies of these rare condi-
tions and of animal models that mimic their enzyme defects
should greatly facilitate an understanding of the functional role
of corneal components and their intermolecular organization.
In addition, clarification of the relationship between genotype
and the clinical and microscopic manifestations of MPS VII
should provide useful information for the development of
effective molecular therapies.
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